Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled lisdexamfetamine augmentation study in inadequate responders with major depressive disorder
2011-003615-28Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lisdexamfetamine in major depressive disorder (MDD) (5 arms), sponsored by Takeda. Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale total score. Started Dec 2012; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-003615-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003615-28.